



American Lamb Council



American Sheep Industry Association, Inc.



American Wool Council

January 19, 1998

015 4 3 '98 JAN 20 09:53

Dockets Management Branch (HFA - 305)  
Food and Drug Administration  
Park Building, Rm. 1-23  
12420 Parklawn Drive  
Rockville, MD 20857

**Re: Docket No. 97N-0217 --"Proposals to Increase the Availability of Approved Drugs for Minor Species and Minor Uses"**

We are writing on behalf of the American Sheep Industry Association (ASI). ASI represents approximately 80,000 sheep producers in the United States through its 50 state member associations as well as product manufacturers and other allied industry groups.

ASI appreciates the opportunity to comment on this discussion draft and the agency's efforts to address options to increase the availability of approved drugs for minor animal species and minor uses. We are disappointed, however, that the agency did not publish in the discussion draft many regulatory options for comment. In fact, of the 11 major initiatives outlined in the draft, nine require legislative actions. It was our understanding, through discussions with the agency during deliberations on the Animal Drug Availability Act of 1996 (ADAA), that CVM had a regulatory framework visualized for making major improvements to the minor species/minor use drug availability problem and needed the 18 months called for in the bill to complete what was well underway. There have been two legislative vehicles, the ADAA and the FDA reform bill, through which legislative changes to affect minor species/minor use could have been approached should the agency have anticipated and proposed these changes earlier. Through the process of analyzing comments on this discussion draft, we encourage CVM to give more serious consideration to regulatory options as was initially indicated.

**Modification of Extra-label Provisions**

We agree with CVM that extra-label use is not the entire solution to the minor species drug availability problem. We reference the comments by the American Feed Industry Association on the use of a Compliance Policy Guide (CPG) as a means for implementing the Veterinary Feed Directive (VFD) under current statutory authority and we agree with their comments. We also reference the comments of the Coalition for Animal Health on this issue and agree with their proposed solution: to amend the VFD provisions of the ADAA rather than amend the Animal Medicinal Drug Use Clarification Act (AMDUCA). We believe that VFD is a clearly defined, well structured process for distributing minor species drugs through feed and could be implemented under current statute using the CPG approach at least as an interim measure. ASI will support amending the ADAA, if necessary, to provide a permanent statutory solution.

97N-0217

D  
C54

Docket No. 97N-0217

January 19, 1998

Concerning the agency's question concerning reproductive hormones and implants; ASI believes that reproductive hormones and implants and other non-therapeutics should be included under extra-label provisions for minor species and minor uses.

### **Removal of Disincentives**

ASI disagrees with the agency's proposals to increase enforcement against unapproved minor species/minor use drugs and its reasoning behind those proposals. We believe that enforcement actions/resources should be no more stringent against minor species/minor use drugs than against major species/major use drugs.

ASI supports amending 21 CFR 514.106 to define supplemental NADAs for the addition of minor species to major species labels as a category that would not trigger critical reviews of the major species data packages.

### **Enhancement of Existing Programs for Data Development**

ASI is on record supporting additional funding for the NRSP-7 program as well as other funding sources. We also encourage CVM to pursue non-therapeutic drug approvals; the sheep industry has serious need of such products. We oppose removing the "food and fiber restriction" on the use of these funds and for the NRSP-7 program. This program has never had sufficient resources to make major contributions to the minor food and fiber species and uses. We feel that food and fiber uses should continue to be the priority.

### **Incentives to Pursue Minor Use Drug Approvals**

ASI agrees with all of the proposed incentives listed under this section and we will support efforts to implement them. We believe that our industry would be better served to have more products available to treat our animals even if there is a risk that cost savings for generic competition is not realized for a longer period of time.

### **Data Sharing By Major Species NADA Holders**

ASI believes that the proposals described in the discussion draft has merit provided the "takings" and liability issues can be reasonably resolved. We encourage CVM to develop this idea further and investigate mechanisms for ameliorating the above-mentioned potential problems.

### **Creation By Statute of a "Minor Use Animal Drug" Program**

ASI supports the creation of a "Minor Use Animal Drug" category similar to the human orphan drug category with all the associated incentives. We supported this approach in the original deliberations on the ADAA. We are under the impression that a minor species/minor use work

Docket No. 97N-0217  
January 19, 1998

unit is, in fact, in existence currently. If this is not the case then we certainly support the development of one for the reasons outlined and structured in the manner described. A minor species/minor use work unit must certainly have adequate resources allocated to it in order for such a unit to have a functional impact.

### **Conditional Drug Approval for Minor Uses Involving Non-food Animals**

ASI is on record supporting a conditional or streamlined approval process and we believe, as is the case with veterinary biologics, such processes could be an important method for moving product approvals into the market place. We believe that the proposals and limitations outlined in the discussion draft would be particularly useful. However, we believe CVM is in error in stating: "Food-producing animals should be excluded from this proposal" and to answer CVMs specific question: "Is the proposed process appropriately restricted to minor uses involving non-food animals?" Our answer is no; the proposed process should include food animals.

### **Alternate Approval Standard/Expert Review Panels for Minor Uses Involving Non-food Animals**

ASI supports the proposals outlined under this section but again believes that CVM is in error in limiting them to non-food producing animals. To answer specific questions: We believe that animal caretakers will find drugs approved under the proposed alternate standard acceptable. The sheep industry does have the ability to assist CVM with expert review panels and would be willing to fund such panels as circumstances allow. As stated above, the proposed process should not be restricted to non-food animals.

### **International Harmonization**

It is appropriately stated in the discussion draft that international harmonization: "could greatly increase the availability of approved drugs for minor uses in the United States". We strongly agree that: "if FDA could accept reviews for minor uses approved in other countries with equivalent regulatory systems, then obtaining approval in the U.S. would be potentially less costly and thus more attractive to sponsors". It is further stated in the discussion draft: "The agency could develop a system to assess the equivalency of approval systems in other countries and could then accept reviews from equivalent systems". ASI sees these statements as both true, positive and in the central spirit of enhanced global competitiveness and trade opportunities. There is precedent in assessing foreign equivalency in meat inspection regulations. The sheep industry is a good example of a species which is minor in the U.S. and which is major in other parts of the world. The opportunities afforded the sheep industry under international harmonization of review processes and data sharing are large. The competitiveness of the U.S. sheep industry can be vastly improved if products available to producers and veterinarians in countries like Australia and New Zealand are available here. We believe that there are sufficient numbers of foreign approvals to warrant the establishment of a CVM program to identify drugs approved in other countries and to

Docket No. 97N-0217

January 19, 1998

work with potential sponsors on data needs. As stated in the discussion draft, no congressional action is required in order to implement these processes and CVM but to add minor species/minor use to current harmonization activities. ASI urges CVM to proceed in implementing all aspects of the international harmonization for minor species/minor use drug approvals with all haste.

ASI appreciates the opportunity to comment on this docket, one which is very important to our industry. We also appreciate CVMs work and support of reforming the approval process for minor species /minor uses. If we can assist the agency in any way, please don't hesitate to contact us.

Submitted by:

Dr. Cindy Wolf  
Chairman, ASI  
Animal Health & Welfare Committee

**FedEx** USA Airbill

Tracking  
Number

2252945940

183417 **Recipient's Copy** 803339/00500

**1 From**   
Date **1/19/97**

Sender's Name **Cindy Wolf** Phone **(303) 771-3500**

Company **AMER SHEEP INDUSTRY ASSOC**

Address **6911 S YOSEMITE ST**

City **ENGLEWOOD** State **CO** Zip **80112**

**2** Your Internal Billing Reference Information

**3 To**  
Recipient's Name **Dockets Mgt Branch \*(HFA-305)** Phone ( )

Company **USDA/FDA** **Park Bldg**

Address **RM 1-23, 12420 Parklawn Dr**

(To "HOLD" at FedEx location, print FedEx address here)

City **Rockville** State **MD** Zip **20857**

**For HOLD at FedEx Location check here**  
☐ **Hold Weekday** (Not available with FedEx First Overnight)  
☐ **Hold Saturday** (Not available at all locations)  
(Not available with FedEx First Overnight or FedEx Standard Overnight)

**For Saturday Delivery check here**  
☐ (Extra Charge. Not available to all locations)  
(Not available with FedEx First Overnight or FedEx Standard Overnight)



**4a Express Package Service Packages under 150 lbs.** Delivery commitment may be later in some areas.  
☐ FedEx Priority Overnight (Next business morning) ☒ FedEx Standard Overnight (Next business afternoon) ☐ FedEx 2Day\* (Second business day)


☐ NEW FedEx First Overnight (Earliest next business morning delivery to select locations) (Higher rates apply) \* FedEx Letter Rate not available. Minimum charge: One pound FedEx 2Day rate

**4b Express Freight Service Packages over 150 lbs.** Delivery commitment may be later in some areas.  
☐ FedEx Overnight Freight (Next business day service for any distance) ☐ FedEx 2Day Freight (Second business day service for any distance) ☐ FedEx Express Saver Freight (Up to 3 business-day service based upon distance)  
(Call for delivery schedule. See back for detailed descriptions of freight products.)


**5 Packaging** ☒ FedEx Letter ☐ FedEx Pak ☐ FedEx Box ☐ FedEx Tube ☐ Other Pkg  
Declared value limit \$500

**6 Special Handling**  
Does this shipment contain dangerous goods? ☐ Yes (As per attached Shipper's Declaration) ☐ Yes (Shipper's Declaration not required)  
☐ Dry Ice (Dry Ice, S. UN 1845 III, kg. 904) CA ☐ Cargo Aircraft Only

**7 Payment** ☐ Obtain Recipient FedEx Account No.  
Bill to: ☒ Sender (Account no. in section 1 will be billed) ☐ Recipient (Enter FedEx account no. or Credit Card no. below) ☐ Third Party ☐ Credit Card ☐ Cash/Check

  
Total Packages Total Weight Total Declared Value \$ .00  
Total Charges \$

\* When declaring a value higher than \$100 per shipment, you pay an additional charge. See SERVICE CONDITIONS, DECLARED VALUE AND LIMIT OF LIABILITY section for further information.

**8 Release Signature**  
  
Your signature authorizes Federal Express to deliver this shipment without obtaining a signature and agrees to indemnify and hold harmless Federal Express from any resulting claims.

**Questions?**  
Call 1-800-Go-FedEx  
(1-800-463-3339)

272

WCSL 0796  
Rev. Date 6/96  
PAH/ #147958  
©1994-96 FedEx  
PRINTED IN U.S.A.